Ventripoint Diagnostics Provides Update on Stock Options

Toronto, Ontario — June 17, 2025 — NewsWall — Ventripoint Diagnostics Ltd. (TSXV:VPT, OTC:VPTDF) has updated its stock option activity. On March 12, 2025, the company issued 500,000 option grants at $0.15 and another 500,000 at $0.20 to contractors, vesting over four months with a two-year term.

On June 2, 2025, Ventripoint issued 2,000,000 option grants at $0.10 to employees, consultants, and advisors, vesting immediately to over three years with terms from two to ten years. Further, on June 12, 2025, 1,635,000 option grants at $0.10 were issued to employees, consultants, and advisors, vesting immediately to over three months with a two-year term. None of these grants were awarded to directors or officers.

Since February 11, 2024, a total of 3,119,450 options were exercised at a weighted average price of approximately $0.11 per share, yielding gross proceeds of $356,385. Additionally, 1,994,500 options expired. Currently, 13,100,750 options are outstanding with exercise prices between $0.10 and $0.50, having a weighted average exercise price of $0.20. Of these, 11,083,250 options have vested.

Ventripoint has approximately 3.5 million options available for future grants under its Stock Option Plan, as approved by shareholders. The company has approximately 166 million shares issued and outstanding.

Hugh MacNaught, President and CEO, can be reached at hmacnaught@ventripoint.com or (604) 671-4201 for further information.

Source: Ventripoint Diagnostics Ltd.